NEW YORK, NY,  August 04, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2022 and raised full-year 2022 guidance for Adjusted Cash Receipts⁽¹⁾ (a non-GAAP financial measure).

NEW YORK, NY, July 15, 2022 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2022 of $0.19 per Class A ordinary share. The dividend will be paid on September 15, 2022, to shareholders of record at the close of business

NEW YORK, NY, July 14, 2022 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2022 financial results on Thursday, August 4, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.

NEW YORK, July 13, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it has agreed to acquire a royalty interest in Trelegy Ellipta (Trelegy) from Theravance Biopharma, Inc. (Nasdaq: TBPH) and Innoviva, Inc. (Nasdaq: INVA) for $1.31 billion in cash up front and up to 

NEW YORK, NY, June 30, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired an ex-U.S. royalty interest in Gavreto (pralsetinib) from Blueprint Medicines (Nasdaq: BPMC) for up to $340 million, consisting of $175 million

NEW YORK, NY, June 8, 2022 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 43 rd Annual Global Healthcare Conference on June 14, 2022 at 2:20 p.m. ET.

NEW YORK, NY, May 23, 2022 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the UBS Global Healthcare Conference 2022 on May 24, 2022 at 1:15 p.m. ET. The webcast will be accessible from Royalty

NEW YORK, NY, May 17, 2022 – Royalty Pharma plc (Nasdaq: RPRX) will host its inaugural Investor Day in New York City today. Royalty Pharma’s management team will provide an update on the company’s capital deployment

NEW YORK , NY,  May 05, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2022 and reaffirmed full-year 2022 guidance for Adjusted Cash Receipts⁽¹⁾ (a non-GAAP financial measure).

NEW YORK, NY, April 18, 2022 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2022 of $0.19 per Class A ordinary share. The dividend will be paid on June 15, 2022, to shareholders of record at the close of business on May